Abstract
Notch signaling plays an important role in tumor angiogenesis. Recent studies suggest that Notch signaling also regulates the progression of primary melanomas toward an aggressive phenotype. The aim of this study was to investigate the involvement of Notch signaling pathway in organization of tumor cells into capillary-like structures (CLS), the phenomenon also known as vasculogenic mimicry (VM). Here, we show that Notch signaling cascade was constitutively active in melanoma cell lines we used. Blocking Notch signaling with the γ-secretase inhibitors, DAPT, dibenzazepine or Jagged1 neutralizing antibody resulted in stabilization of CLS indicating that Notch signaling pathway attenuates melanoma VM. We further studied this phenomenon on melanomas grafted in nude mice. Compared to control, VM channels in DAPT-treated grafted melanoma became larger and more branched. DAPT-treated melanomas also exhibited an up-regulation of MMP-2 and VEGFR1, both known as VM mediators. Moreover, we did not observe necrosis in VM channels areas of DAPT-treated melanomas. These findings indicate that VM regulated by Notch signaling may present a novel target in melanoma therapy.
Similar content being viewed by others
Abbreviations
- VEGFR:
-
Vascular endothelial growth factor receptor
- VM:
-
Vasculogenic mimicry
- CLS:
-
Capillary-like structure
- PAS:
-
Periodic Acid-Schiff reagent
- EC:
-
Endothelial cells
- MVD:
-
Microvascular density
- ECM:
-
Extracellular matrix
- PBS:
-
Phosphate buffer solution
- RPMI 1640:
-
Roswell Park Memorial Institute 1640
- Mel Kor:
-
Mel Cher and Mel P -melanoma cell lines, derived from surgical species of patients with disseminated melanoma
References
Feige JJ (2010) Tumour angiogenesis: recent progress and remaining challenges. Bull Cancer 97(11):1305–1310
Hiratsuka S (2011) Vasculogenesis, angiogenesis and special features of tumour blood vessels. Front Biosci 16:803–814
Quesada AR, Medina MA, Munoz-Chapuli R, Ronce AL (2010) Do not say ever never more: the ins and outs of antiangiogenic therapies. Curr Pharm Des 16(35):3932–3957
Sharma PS, Sharma R, Tyagi T (2011) VEGF/VEGFR pathway inhibitors as anti-angiogenic agents: present and Future. Curr Cancer Drug Targets 11(5):624–633
Gerger A, LaBonte M, Lenz HL (2011) Molecular predictors of response to antiangiogenesis therapies. Cancer J 17(2):134–141
Fan YZ, Sun W (2010) Molecular regulation of vasculogenic mimicry in tumours and potential tumor-target therapy. World J Gastrointest Surg 2(4):117–124
Paulis YW, Soetekouw PM, Verheul HM (2010) Signaling pathways in vasculogenic mimicry. Biochem Biophys Acta 1806(1):18–28
Schwanbeck R, Martini S, Bernoth K, Just U (2011) The Notch signalling pathway: molecular basis of cell content dependency. Eur J Cell Biol 90(6–7):572–581
Eiken HM, Adams RM (2010) Dynamics of endothelial cell behaviour in sprouting angiogenesis. Curr Opin Cell Biol 22(5):617–625
Koch U, Radtke F (2010) Notch signaling in solid tumor. Curr Top Dev Biol 92:367–409
Guo S, Liu M, Gouzalez-Perez RR (2011) Role of Notch and its oncogenic signaling crosstalk in breast cancer. Biochem Biophys Acta 1815(2):197–213
Aster JC, Blacklow SC, Pear WS (2011) Notch signalling in T-cell lymphoblastic leukaemia/lymphoma and other haematological malignancies. J Pathol 223(2):262–273
Sjolund J, Johanson M, Manna S, Norin C, Pietras A, Beckman S et al (2008) Suppression of renal cell carcinoma growth by inhibition of Notch signalling in vitro and in vivo. J Clin Invest 118(1):217–228
Massi D, Tarantini F, Franchi A, Paglierani M, Serio Di, Pellerito S et al (2006) Evidence for differential expression of Notch receptors and their ligands in melanocytic nevi and cutaneous malignant melanoma. Modern Pathol 19:246–254
Jabobsson L, Bentley K, Gerhardt U (2009) VEGFRs and Notch: a dynamic collaboration in vascular patterning. Biochem Soc Trans 37(6):216–233
Cristofaro B, Emanueli C (2009) Possible novel targets for theraupetic angiogenesis. Curr Opin Pharmacol 9(2):102–108
Mikhailova IN, Lukashina MI, Baryshnikov AYu, Morozova LF, Kiselev CL, Georgiev GP (2005) Melanoma cell lines as the basis for antitumor vaccine preparation. Vest Ross Akad Med Nauk 7:37–40
Mikhailova IN, Kovalevsky DA, Morozova LF, Burova OS, Baryshnikov AYu, Bibilashvili RS (2008) Cancer/testis genes expression in human melanoma cell lines. Mel Res 18(5):303–313
Vartanian A, Burova O, Stepanova E, Baryshnikov AYu, Lichinitser MR (2007) The involvement of apoptosis in melanoma vasculogenic mimicry. Mel Res 17:1–8
Gridley T (2010) Notch signalling in the vasculature. Curr Top Dev Biol 92:277–309
Liu Z, Xiao M, Balint K, Smally K, Bradford P, Qiu R et al (2006) Notch signalling promotes primary melanoma progression by activating Mitogen-activated protein kinase/phosphatidylinosotol 3-kinase-Akt pathway and upregulate N-cadherin expression. Cancer Res 66:4182–4190
Kame T (2009) Novel insights into the differentiatial funcrions of Notch ligands in vascular formation. J Angiogeneisi Res 16:1–8
Luistro L, He W, Smith M, Packman K, Vilenchik M, Carvajal D et al (2009) Preclinical profile of a potent γ-secretase inhibitor targeting Notch signalling with in vivo efficacy and pharmacodynamic properties. Cancer Res 68(19):7672–7680
Hess AR, Seftor EA, Seftor RE, Hendrix MJ (2003) Phosphoinositide 3-kinase regulates membrane type 1-matrix metalloproteinase (MMP) and MMP-2 activity during melanoma cell vasculogenic mimicry. Cancer Res 63:4757–4762
Vartanian A, Stepanova E, Grigorieva I, Solomko E, Baryshnikov A, Lichinitser M (2011) VEGFR1 and PKCalpha signalling control melanoma vasculogenic mimicry in a VEGFR2 kinase-independent manner. Mel Res 21(2):91–98
Frank NY, Schatton T, Kim S, Zhan Q, Wilson BJ, Ma J (2011) VEGFR1 expressed by malignant melanoma-initiating cells is required for tumor growth. Cancer Res 71(4):1474–1485
Helfrich E, Schadendorf D (2011) Blood vessel maturation, vascular phenotype and angiogenic potential in malignant melanoma: one step forward for overcoming anti-angiogenic resistance? Mol Oncol 5:137–149
Ko JM, Verez NF (2010) Tsao H Pathways to melanoma. Semin Cutan Med Surg 29(4):210–217
Folberg R, Maniotis AJ (2004) Vasculogenic mimicry. Apmis 112:508–525
Yan M, Plowman GB (2007) Delta-like 4/Notch signalling and its theraupetic implications. Cancer Res 13(24):7243–7246
Hardy KM, Kirschmann DA, Seftor EA, Margaryan NV, Postovit LM, Hendrix MJ (2010) Regulation of the embryonic morphogen Nodal by Notch facilitates manifestation of the aggressive melanoma phenotype. Cancer Res 70(24):1034010350
Paez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Vinals F et al (2009) Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15:220–231
Acknowledgments
The authors are grateful to I. Prudovsky for critical reading the MS, valuable comments and good advice
Conflict of interest
The authors state no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Additional information
This work was supported by an award to M.R. Lichinitser from the Foundation for Russian Ministry of Education and Science 02.512.11.2195.
Rights and permissions
About this article
Cite this article
Vartanian, A., Gatsina, G., Grigorieva, I. et al. The involvement of Notch signaling in melanoma vasculogenic mimicry. Clin Exp Med 13, 201–209 (2013). https://doi.org/10.1007/s10238-012-0190-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10238-012-0190-9